Caris Life Sciences delivered a Q1 revenue beat and reaffirmed full-year guidance, then watched its stock collapse anyway — down 19% the day after results and 13% on the week to $16.15.
The gap between the reported numbers and the market's reaction is the week's central tension. Q1 sales of $216.2 million cleared the $210.3 million consensus. Full-year guidance of $1.00–$1.02 billion bracketed the $1.01 billion estimate. On paper, that is a reassuring print. The market answered with one of its sharpest single-day drops since listing. That kind of punish-the-beat response usually reflects something beyond the headline numbers — whether margin trajectory, reimbursement risk, or simply a valuation that had priced in more.
The analyst reaction tells a clear story: the conviction stays bullish, but the price targets have moved decisively lower. JP Morgan held its Overweight but trimmed to $30 from $35. Citigroup kept its Buy and cut to $28 from $35. BTIG maintained Buy and moved to $32 from $38. Every firm that spoke on Friday held its positive rating. Every one of them cut the target. That uniform target compression — while preserving buy calls — suggests analysts still believe the underlying business is working, but the multiple needs to deflate to match a harder near-term path. The mean target now sits at $28.62 against a stock at $16.15, implying roughly 77% upside on the Street's numbers. That gap is wide, but it widened in a single session — treat it with appropriate caution rather than as a clean signal.
Short positioning tells a more measured story than the price action implies. Short interest edged up just 0.24% on the day of the results, leaving it at 4.0% of the free float — elevated enough to matter but not at extremes. Borrow is cheap at 0.79% annualised, and the lending market is well-supplied: availability runs at roughly 117% of short interest, meaning there are more shares available to borrow than are currently shorted. That is well above the tight end of the range. Availability has also been loosening steadily since mid-April, when utilisation was running in the upper 60s. The ORTEX short score of 68.8 is notable — elevated and rising slowly — but still well below the maximum the stock has hit in its short history on exchange. Shorts were not crowded ahead of this result, and the data does not show a meaningful rush to add exposure immediately after.
Options have been consistently defensive for weeks. The put/call ratio runs at 1.34, nearly identical to its 20-day average of 1.34, with a z-score almost exactly zero — meaning the defensive skew is persistent but not at an extreme. The 52-week high for PCR was 1.73, hit on April 30, and the ratio has pulled back modestly since. Options traders were already hedged before the earnings date; Friday's drop appears to have been less an options-driven event than a straight equity selling episode.
From an ownership perspective, FMR (Fidelity) added 16.4 million shares in the most recent quarter, lifting its stake to 10.8% and making it the second-largest holder. That is a substantial accumulation — the largest reported institutional move on the register. Founder and Chairman/CEO David Halbert controls 43.4% of shares, a concentration that limits float and may amplify price swings in both directions. The most recent insider data is stale (December 2025) and predates the post-IPO sell-down cluster from August 2025, so it offers little signal on current management conviction.
There is also a positive regulatory development worth watching. Caris submitted an application to the New York State Department of Health's Clinical Laboratory Evaluation Program for authorisation to perform Caris Assure on New York specimens — a key reimbursement and access gateway in one of the country's largest patient markets. Combined with the earlier MolDX approval for ChromoSeq announced on May 4, the company is actively building its regulatory coverage map. The next earnings event is scheduled for May 22 — just two weeks away. Given the stock's 15.6% post-results drop on Thursday and the prior event showing a 4.7% gain, the range of outcomes at the next print will be watched closely.
See the live data behind this article on ORTEX.
Open CAI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
